The Lindner Center for Research & Education at The Christ Hospital
Welcome,         Profile    Billing    Logout  
 12 Trials 
27 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kereiakes, Dean
NCT02806570: The CorCinch - Functional Mitral Valve Regurgitation (FMR) Study

Completed
N/A
35
US
Mitral valve repair
Ancora Heart, Inc.
Heart Failure, Mitral Valve Insufficiency, Cardiomyopathies
01/20
08/24
NCT03168776: PIONEER III Trial to Assess Safety and Efficacy of the BuMA Supreme™ Drug Coated Coronary Stent in Patients With Coronary Disease

Active, not recruiting
N/A
1632
Europe, Canada, Japan, US
BuMA Supreme DES, Xience or Promus DES
Sino Medical Sciences Technology Inc., Nova Vascular LLC
Coronary Artery Disease
10/20
09/24
NCT02799823: Transfemoral Replacement of Aortic Valve With HLT MeriDIAN Valve Early Feasibility Trial

Terminated
N/A
11
US
HLT Transcatheter Aortic Valve System
HLT Inc.
Aortic Valve Stenosis
01/23
01/23
RIVAL - AR EFS, NCT05409378: HLT® Meridian® TAVR Valve System Early Feasibility Study for Aortic Regurgitation

Withdrawn
N/A
10
US
The HLT® Meridian® TAVR Valve (Meridian® with TriVentTM Anticalcification Treatment Valve and Pathfinder® Delivery System)
HLT Inc.
Aortic Regurgitation
01/23
01/23
CRYSTAL, NCT03423511: Trial to Demonstrate the Safety and Effectiveness of the MiStent II for the Revascularization of Coronary Arteries.

Not yet recruiting
N/A
1300
NA
MiStent II coronary artery stent, Xience or Promus coronary artery stents
Micell Technologies, Baim Institute for Clinical Research, North American Science Associates Inc., Yale Cardiovascular Research Group
Coronary Artery Disease
06/23
06/27
JVTF EFS, NCT06034028: J-Valve TF Early Feasibility Study

Active, not recruiting
N/A
25
US
J-Valve TF System
JC Medical, Inc.
Aortic Valve Disease, Aortic Valve Insufficiency, Aortic Regurgitation
07/24
08/29
CorCinch-HF, NCT04331769: Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present with Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF): the CORCINCH-HF Study

Recruiting
N/A
400
Europe, US, RoW
AccuCinch Ventricular Restoration System, Guideline-Directed Medical Therapy
Ancora Heart, Inc.
Heart Failure with Reduced Ejection Fraction (HFrEF), Dilated Cardiomyopathy
12/26
12/30
JOURNEY, NCT06455787: J-Valve Transfemoral Pivotal Study

Recruiting
N/A
194
US
J-Valve Transfemoral (TF) System
JC Medical, Inc., Bright Research Partners, Minneapolis Heart Institute Foundation, Cardiovascular Research Foundation, New York
Aortic Valve Regurgitation, Aortic Valve Disease Mixed
09/27
09/31
NCT04496518: Personalized Therapy Study - Intrinsic Antitachycardia Pacing Post-Approval Study (iATP PAS)

Active, not recruiting
N/A
2200
Europe, US
Intrinsic Antitachycardia Pacing (iATP) Therapy
Medtronic
Ventricular Tachycardia
01/25
01/27
NCT04489225: Personalized Therapy Study - HFRS (TriageHF) Post Approval Study

Active, not recruiting
N/A
2200
Europe, US
Observational
Medtronic
Heart Failure
01/25
01/27
NCT03142152: The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With at Least Mild FMR

Recruiting
N/A
300
Europe, US
Carillon Mitral Contour System, Carillon, Percutaneous mitral valve repair, Guideline Directed Heart Failure Medication
Cardiac Dimensions, Inc.
Functional Mitral Regurgitation, Heart Failure, Mitral Valve Insufficiency, Heart Diseases, Cardiovascular Diseases, Heart Valve Diseases
12/26
12/30
ASQ, NCT04024943: Personalized Therapy Study - Attain Stability Quad Post-Approval Study

Active, not recruiting
N/A
1092
Europe, US
Quadripolar LV Lead, Medtronic CRT-P, Medtronic CRT-D
Medtronic
Heart Failure
01/27
04/27
NCT06048731: Enlighten Study: The EV-ICD Post Approval Registry

Recruiting
N/A
1000
Europe, Canada, US, RoW
Defibrillation using EV-ICD
Medtronic
Ventricular Arrhythmia, Tachycardia
05/30
10/37
Starodub, Alexander N
CompassHER2 RD, NCT04457596: T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC V8, Anatomic Stage II Breast Cancer AJCC V8, Anatomic Stage IIA Breast Cancer AJCC V8, Anatomic Stage IIB Breast Cancer AJCC V8, Anatomic Stage III Breast Cancer AJCC V8, Anatomic Stage IIIA Breast Cancer AJCC V8, Anatomic Stage IIIB Breast Cancer AJCC V8, Anatomic Stage IIIC Breast Cancer AJCC V8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC V8, Prognostic Stage IA Breast Cancer AJCC V8, Prognostic Stage IB Breast Cancer AJCC V8, Prognostic Stage II Breast Cancer AJCC V8, Prognostic Stage IIA Breast Cancer AJCC V8, Prognostic Stage IIB Breast Cancer AJCC V8, Prognostic Stage III Breast Cancer AJCC V8, Prognostic Stage IIIA Breast Cancer AJCC V8, Prognostic Stage IIIB Breast Cancer AJCC V8, Prognostic Stage IIIC Breast Cancer AJCC V8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
GRANITE, NCT05141721: A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Active, not recruiting
2/3
700
US
GRT-C901, GRT-R902, Atezolizumab, Tecentriq, Ipilimumab, Yervoy, Fluoropyrimidine plus leucovorin, Xeloda, Bevacizumab, Avastin
Gritstone bio, Inc.
Colorectal Neoplasms
03/27
03/27
NCT04759664: LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC

Recruiting
2
117
US, RoW
LUT014 Gel (Dose 1), LUT014 Gel (Dose 2), Placebo
Lutris Pharma Ltd.
EGFRI Induced Acneiform Lesions
03/24
05/24
BA3011-002, NCT04681131 / 2022-000135-23: CAB-AXL-ADC Safety and Efficacy Study in Adults with NSCLC

Active, not recruiting
2
240
Europe, US, RoW
CAB-AXL-ADC, BA3011, PD-1 inhibitor
BioAtla, Inc., BioAtla Inc.
Non-Small-Cell Lung Cancer
08/25
08/25
BOLSTER, NCT05712356: A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors

Recruiting
2
80
Europe, US
LSTA1, certepetide, CEND-1, Durvalumab, Imfinzi, Cisplatin, Gemcitabine, FOLFOX regimen, Oxaliplatin, Folinic acid, Fluorouracil, Placebo
Lisata Therapeutics, Inc.
Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Bile Duct Cancer, Gall Bladder Cancer, Gall Bladder Carcinoma
03/26
03/26
NAPISTAR1-01, NCT06303505: FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

Recruiting
1/2
100
Europe, US
TUB-040
Tubulis GmbH
Ovarian Cancer, Non-small Cell Lung Cancer
01/27
01/27
BA3011-001, NCT03425279: CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients with Sarcoma

Active, not recruiting
1/2
300
US, RoW
CAB-AXL-ADC, PD-1 inhibitor
BioAtla, Inc.
Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma
01/25
01/25
CaRe, NCT06056791: Study of INKmune in Patients With mCRPC ( Prostate)

Recruiting
1/2
30
US
INKmune
Inmune Bio, Inc.
Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC
05/25
11/25
BA3021-001, NCT03504488 / 2022-000137-17: CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

Completed
1/2
132
Europe, US, RoW
CAB-ROR2-ADC, BA3021, PD-1 inhibitor
BioAtla, Inc., BioAtla Inc.
Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer
12/24
12/24
DB-1310-O-1001, NCT05785741: A Study of DB-1310 in Advanced/Metastatic Solid Tumors

Recruiting
1/2
1000
US, RoW
DB-1310, Trastuzumab, Osimertinib
DualityBio Inc.
Advanced Solid Tumor
08/26
08/26
NCT05144334: A Study of BTX-1188 in Subjects With Advanced Malignancies

Terminated
1
8
US
BTX-1188
BioTheryX, Inc.
Advanced Solid Tumor, Non Hodgkin Lymphoma, Acute Myeloid Leukemia
09/23
09/23
NCT05159700: A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors

Completed
1
39
US
PRJ1-3024
Zhuhai Yufan Biotechnologies Co., Ltd
Advanced Solid Tumor, Advanced Solid Malignancies
07/24
10/24
BTX-A51-002, NCT04872166: A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer

Recruiting
1
112
US
BTX-A51
Edgewood Oncology Inc.
Advanced Solid Tumor, Metastatic Breast Cancer
05/26
05/27
NCT06096974: Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS

Not yet recruiting
1
60
US
YL-17231
Shanghai YingLi Pharmaceutical Co. Ltd.
Advanced Solid Tumors
04/25
04/26
Sikora, Terri
No trials found

Download Options